Clinical trial · Interventional
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
International Phase II Studies of I-mIBG in Combination With Topotecan and Peripheral Blood Stem Cell Rescue for (A) Primary Resistant High Risk Neuroblastoma and (B) Relapsed Stage 4 Neuroblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Withdrawn because protocol has been discontinued. It was never opened.
Summary
Brief summary (as posted)
RATIONALE: Radioisotope therapy, such as iodine I 131 metaiodobenzylguanidine (MIBG), releases radiation that kills tumor cells. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Topotecan may also make tumor cells more sensitive to iodine I 131 MIBG. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by iodine I 131 MIBG and topotecan. This may allow more iodine I 131 MIBG and topotecan to be given so that more tumor cells are killed. PURPOSE: This phase II trial is studying how well giving high-dose iodine I 131 MIBG together with topotecan and peripheral stem cell transplant works in treating young patients with relapsed stage 4 neuroblastoma or primary resistant high-risk neuroblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy | Procedure | — | UNRESOLVED |
| iodine I 131 metaiodobenzylguanidine | Drug | — | UNRESOLVED |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radioisotope therapy | Procedure | — | UNRESOLVED |
| radionuclide imaging | Procedure | — | UNRESOLVED |
| radiosensitization | Procedure | — | UNRESOLVED |
| topotecan hydrochloride | Drug | Topotecan | ALIAS |
| total-body irradiation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Proportion of patients who respond to treatment (partial response and complete response at metastatic sites) as measured by metaiodobenzylguanidine scintigraphy and positron emission tomography and CT imaging
- measure
- Proportion of patients who are able to progress to potentially curative treatment with surgery and further systemic treatment
- measure
- Correlation of tumor dosimetry with response
- measure
- Time to tumor progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 17 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Confirmed diagnosis of neuroblastoma meeting the 1 of the following criteria:
* Primary resistant high-risk disease meeting the following criteria:
* International neuroblastoma staging system (INSS) stage 4, or stage 2 or 3 with myelocytomatosis viral-related oncogene (MycN) amplification
* Failed to achieve satisfactory remission with induction chemotherapy, defined as one of the following:
* Less than 50% reduction or \> 3 positive sites on iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) scintigraphy
* Persistent cytomorphological positive disease in bone marrow aspirates or trephine biopsies
* Progressive disease necessitating a change of treatment
* Relapsed stage 4 disease meeting the following criteria:
* High-risk neuroblastoma (INSS stage 4, or stage 2 or 3 with MycN amplification)
* Relapsed after intensive treatment including high-dose chemotherapy and hematopoietic progenitor cell support
* Patients may be entered at the time of relapse, or at any point subsequently after other treatments
* \^131I-MIBG-positive disease on diagnostic scintigraphy
* Peripheral blood stem cell harvest ≥ 300,000/mm³ CD 34+ cells
* Enrolled in or has been treated on protocol SIOP-NB-2009 or a similar protocol
PATIENT CHARACTERISTICS:
* Glomerular filtration rate ≥ 50 mL/min
* Considered fit enough to undergo proposed study treatment
PRIOR CONCURRENT THERAPY:
* See Disease CharacteristicsReferences
Publications (0)
Data not yet available